Fig. 5
From: Glycerol kinase 5 confers gefitinib resistance through SREBP1/SCD1 signaling pathway
GK5 knockdown suppresses tumor cell proliferation in vivo. a Nude mice with tumors one month after injection of PC9R cells expressing GK5-shRNA (shGK5–1) or negative control (shNEG). b Tumor volume measured once a week. c Quantitative analysis on tumor weight of shGK5–1 or shNEG groups. d Ki67 expression in xenograft tumors. e Quantitative analysis of Ki67-positive cells. N = 10 mice per group. * p < 0.05 vs. shNEG